See the DrugPatentWatch profile for Esperoct
Esperoct is a recombinant factor eight (FVIII) replacement therapy used to treat hemophilia A [1].
How does Esperoct work for hemophilia A?
Esperoct is an extended-half-life (EHL) FVIII replacement therapy. It is engineered to circulate in the bloodstream for a longer duration compared to conventional FVIII therapies, reducing the frequency of infusions required for patients [2]. This is achieved through a proprietary fusion technology that links FVIII to a modified von Willebrand factor (VWF) [3].
What is the difference between Esperoct and standard FVIII treatments?
Standard FVIII treatments require more frequent infusions, often several times a week, to maintain adequate FVIII levels in the blood and prevent bleeding episodes. Esperoct's extended half-life means patients may need infusions only once or twice a week, depending on their treatment regimen [2].
When does Esperoct's patent protection expire?
Information regarding the specific patent expiry dates for Esperoct is available through specialized patent databases. DrugPatentWatch.com tracks patent statuses and expiry timelines for pharmaceutical products, including those for hemophilia treatments [4].
Who manufactures Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
What clinical data supports Esperoct's use?
Clinical trials have demonstrated that Esperoct is effective in reducing the annualized bleeding rate (ABR) in previously treated adolescents and adults with severe hemophilia A. It is also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes [3].
What are the potential risks or side effects of Esperoct?
As with other FVIII products, potential risks include allergic reactions, including anaphylaxis. The development of inhibitors (neutralizing antibodies) to FVIII is also a possibility in patients with hemophilia A, which can make treatment less effective [3].
Can Esperoct be used for previously untreated patients?
Esperoct is indicated for routine prophylaxis in previously treated adolescents and adults. Its use in previously untreated patients would require further clinical evaluation [3].
What is the pricing of Esperoct?
Pricing for hemophilia A treatments like Esperoct can vary based on geographic location, insurance coverage, and negotiated agreements between manufacturers and healthcare providers. Detailed pricing information is typically obtained through pharmaceutical companies or healthcare benefit managers.
Are there alternatives to Esperoct for hemophilia A?
Yes, there are several alternative treatments for hemophilia A. These include conventional FVIII replacement therapies, other extended-half-life FVIII products, and non-factor replacement therapies such as emicizumab, which is a bispecific antibody that mimics the cofactor activity of FVIII [5].
---
Sources:
[1] https://www.esperoct.com/
[2] https://www.novonordisk.com/patients/patients-with-haemophilia/esperoct.html
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct
[4] https://drugpatentwatch.com/
[5] https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a/treatment-of-hemophilia-a